People with kidney problems may not be able to use Aldactone. Gonadotropin-releasing hormone (GnRH) agonists block the release of a hormone called GnRH that directs testosterone production.

A new study found less than .1% of transgender and gender-diverse teens are prescribed puberty blockers or gender-affirming ...

traditionally a gonadotropin releasing hormone (GnRH) agonist is employed during the stimulation cycle, which, following an initial flare, causes downregulation of the hypothalamic pituitary ...

CESSATION of gonadotropin-releasing hormone antagonist (GnRH-ant) on trigger day in the GnRH-ant protocol improves the ...

Eight patients (3 F, 5 M) have been treated with low dose pulsatile GnRH to induce puberty using ... to progress due to 'down regulation'. Plasma testosterone in the boy increased from <1 to ...

The intended therapeutic effect of gonadotropin-releasing-hormone (GnRH) agonists is hypogonadism, which is a leading cause of osteoporosis in men. Observations are consistent with this effect ...

Researchers say they have identified several factors that may be associated with inadequate ovarian function suppression among premenopausal breast cancer patients receiving endocrine therapy and a ...

GnRH agonists achieve their effect in endometriosis ... rather than by simply suppressing an endogenous hormone such as oestrogen,” concludes Falcone.

Researchers utilize explainable artificial intelligence to identify follicle sizes important for relevant downstream clinical ...

The FDA has granted Fast Track designation to LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis.